focus trial semaglutide Why weight-loss drugs became more popular than ever this year Semaglutide (OZEMPIC®/WEGOVY®) Protocol for Effective

With this flurry of activity, were probably going to see some very exciting new medicines that could be even better than the ones we have now.

Preliminary safety reporting indicated: GI adverse event profile consistent with Phase 2 data No new safety signals identified beyond those observed in earlier trials Discontinuation rates due to adverse events were comparable to other GLP-1 class trials Full adverse event tables from TRIUMPH-4 are expected with the peer-reviewed publication

This plateau does not mean the medication has stopped workingit reflects your body reaching a new metabolic equilibrium

The first three cases were reported among people taking Ozempic, which is approved for type 2 diabetes but used off-label for weight loss, and Saxenda, cleared for weight loss, the EMA said Monday